| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement to Referees
|
|
|
2017
|
12 |
6 |
p. 705-708
|
artikel
|
| 2 |
Acknowledgement to Referees
|
|
|
|
12 |
6 |
p. 705-708
|
artikel
|
| 3 |
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
|
Wainberg, Zev A.
|
|
2017
|
12 |
6 |
p. 775-785
|
artikel
|
| 4 |
Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments
|
Nagayama, Aiko
|
|
2017
|
12 |
6 |
p. 719-739
|
artikel
|
| 5 |
Author’s Reply to Arnaud Uguen: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”
|
Auliac, Jean-Bernard
|
|
2017
|
12 |
6 |
p. 841-842
|
artikel
|
| 6 |
CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer
|
Sunakawa, Yu
|
|
2017
|
12 |
6 |
p. 787-794
|
artikel
|
| 7 |
Comment on: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”
|
Uguen, Arnaud
|
|
2017
|
12 |
6 |
p. 839-840
|
artikel
|
| 8 |
Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database
|
Gouverneur, Amandine
|
|
2017
|
12 |
6 |
p. 805-814
|
artikel
|
| 9 |
Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase
|
Chang, Xiaohui
|
|
2017
|
12 |
6 |
p. 827-832
|
artikel
|
| 10 |
Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)
|
Auliac, Jean-Bernard
|
|
2017
|
12 |
6 |
p. 833-838
|
artikel
|
| 11 |
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
|
van Erp, Anke E. M.
|
|
2017
|
12 |
6 |
p. 815-826
|
artikel
|
| 12 |
Targeting FGFR in Squamous Cell Carcinoma of the Lung
|
Hashemi-Sadraei, Neda
|
|
2017
|
12 |
6 |
p. 741-755
|
artikel
|
| 13 |
The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions
|
Qin, Angel
|
|
2017
|
12 |
6 |
p. 709-718
|
artikel
|
| 14 |
The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors
|
Amair-Pinedo, Fabiola
|
|
2017
|
12 |
6 |
p. 757-774
|
artikel
|
| 15 |
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
|
Di Costanzo, Giovan Giuseppe
|
|
|
12 |
6 |
p. 795-803
|
artikel
|
| 16 |
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
|
Di Costanzo, Giovan Giuseppe
|
|
2017
|
12 |
6 |
p. 795-803
|
artikel
|
Tijdschrift beschrijving